Compare Invesco Galaxy Bitcoin ETF (BTCO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Galaxy Bitcoin ETF vs Crispr Therapeutics AG — how do they compare? Invesco Galaxy Bitcoin ETF trades at $62.97, while Crispr Therapeutics AG trades at $54.28 (market cap $5.23B). The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BTCO | CRSP | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $125.14 | $76.78 |
52-Week Low | $58.40 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTCO shares trade at $63.00, down 0.97% with technical indicators showing a bullish bias despite mixed signals. The stock faces resistance at $65 with support at $64, while moving averages suggest upward momentum. Recent market sentiment reflects cautious optimism amid broader financial market volatility.
The stock's outlook remains uncertain with technical strength countered by fundamental data gaps. Investment opportunity hinges on upcoming financial disclosures, while risks include market volatility and competitive pressures in the company's sector.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
